122 related articles for article (PubMed ID: 8833762)
1. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment.
Hurley MJ; Jolkkonen J; Stubbs CM; Jenner P; Marsden CD
Brain Res; 1996 Feb; 709(2):259-64. PubMed ID: 8833762
[TBL] [Abstract][Full Text] [Related]
2. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
3. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
Lastres-Becker I; Cebeira M; de Ceballos ML; Zeng BY; Jenner P; Ramos JA; Fernández-Ruiz JJ
Eur J Neurosci; 2001 Dec; 14(11):1827-32. PubMed ID: 11860478
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
5. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies.
Morissette M; Goulet M; Grondin R; Blanchet P; Bédard PJ; Di Paolo T; Lévesque D
Eur J Neurosci; 1998 Aug; 10(8):2565-73. PubMed ID: 9767387
[TBL] [Abstract][Full Text] [Related]
6. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
7. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.
Jolkkonen J; Jenner P; Marsden CD
Brain Res Mol Brain Res; 1995 Sep; 32(2):297-307. PubMed ID: 7500841
[TBL] [Abstract][Full Text] [Related]
8. Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease.
Kunikowska G; Jenner P
Brain Res; 2003 Apr; 968(2):206-18. PubMed ID: 12663090
[TBL] [Abstract][Full Text] [Related]
9. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease.
Hurley MJ; Stubbs CM; Jenner P; Marsden CD
Neurosci Lett; 1996 Aug; 214(2-3):75-8. PubMed ID: 8878087
[TBL] [Abstract][Full Text] [Related]
10. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
Gnanalingham KK; Milkowski NA; Smith LA; Hunter AJ; Jenner P; Marsden CD
Eur J Pharmacol; 1995 Apr; 277(2-3):235-41. PubMed ID: 7493614
[TBL] [Abstract][Full Text] [Related]
11. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
Alexander GM; Schwartzman RJ; Grothusen JR; Brainard L; Gordon SW
Brain Res; 1993 Oct; 625(2):276-82. PubMed ID: 8275309
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride.
Booze RM; Wallace DR
Synapse; 1995 Jan; 19(1):1-13. PubMed ID: 7709338
[TBL] [Abstract][Full Text] [Related]
13. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Graham WC; Sambrook MA; Crossman AR
Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
[TBL] [Abstract][Full Text] [Related]
15. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Robertson RG; Clarke CA; Boyce S; Sambrook MA; Crossman AR
Brain Res; 1990 Oct; 531(1-2):95-104. PubMed ID: 2289139
[TBL] [Abstract][Full Text] [Related]
16. Identification of D3 and sigma receptors in the rat striatum and nucleus accumbens using (+/-)-7-hydroxy-N,N-di-n-[3H]propyl-2-aminotetralin and carbetapentane.
Wallace DR; Booze RM
J Neurochem; 1995 Feb; 64(2):700-10. PubMed ID: 7830063
[TBL] [Abstract][Full Text] [Related]
17. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
18. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Riahi G; Morissette M; Samadi P; Parent M; Di Paolo T
Biochem Pharmacol; 2013 Oct; 86(7):970-8. PubMed ID: 23954709
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
20. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
Samadi P; Grégoire L; Morissette M; Calon F; Hadj Tahar A; Bélanger N; Dridi M; Bédard PJ; Di Paolo T
Neuropharmacology; 2008 Feb; 54(2):258-68. PubMed ID: 18001807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
